Medicus Pharma Ltd. Common Stock logo

Medicus Pharma Ltd. Common Stock(MDCX)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$1.95
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for MDCX

11/13/2026: MDCX (1-star) is currently NOT-A-BUY. Pass it for now.

Medicus Pharma Ltd. is a clinical-stage life sciences company focused on advancing specialized therapeutic assets, including its Phase 2 dermatological treatment SKNJCT-003 and the licensed oncology antibody-drug conjugate CD228V. The company's main strengths lie in its promising pipeline and experienced leadership team aiming to address major unmet medical needs. However, primary risks include a complete absence of product revenue, ongoing net operating losses, and high dependency on external financing. The stock suits risk-tolerant investors seeking speculative biotech exposure driven by upcoming clinical data catalysts. Market participants should closely monitor clinical trial readouts, cash burn rates, and capital-raising announcements.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitOffers potential high-growth exposure from clinical milestones, tempered by high execution and dilution risks.
Momentum investorStrong fit while signal remains positiveShort-term traders frequently target the stock around clinical data catalysts and corporate announcements.
Value investorWeak fitThe absence of revenue, ongoing operating losses, and negative earnings make it unsuitable for traditional value metrics.
Dividend investorWeak fitThe company pays no dividends and retains all capital for drug development.
Low-risk investorWeak fitHigh share price volatility and binary clinical trial outcomes expose investors to significant capital loss.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighMicro-cap clinical biotech stocks experience sharp price fluctuations based on news flow and market sentiment.
Valuation riskHighValuation relies heavily on speculative clinical success rather than established cash flows or sales.
Competition risk (large pharma and biotech drug developers)HighWell-funded competitors can out-resource and out-market smaller development-stage entities.
Business qualityMediumThe pipeline holds scientific promise, but commercial validation is yet to be established.
Dividend incomeLow / noneNo dividend yield is available or expected for the foreseeable future.
Execution riskHighClinical trial success, regulatory approvals, and capital raising must be successfully executed to survive.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 3.75M USD
Price to earnings Ratio -
1Y Target Price 32.5
Price to earnings Ratio -
1Y Target Price 32.5
Volume (30-day avg) 86.7K shares
Beta 0.15
52 Weeks Range 1.63 - 127.50
Updated Date 11/15/2026
52 Weeks Range 1.63 - 127.50
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -76.65

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Drug Manufacturers - General

BUY participation
77.8%
Active BUY / eligible
7 / 9
30-Day BUY Count Change
+4

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -44.18%
Avg. Invested days 16
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
MDCX receives a 3-star rating based on the available scored pillars. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
MDCX has moderate overall fundamentals (3 stars), with moderate financial health, soft growth momentum, and solid ownership. In FY2025 versus FY2024, growth and ownership metrics are mixed: negative earnings growth (-127.4%), soft cash generation (FCF margin 0.0%), slightly negative revenue growth (+0.0%).

Financial Health Rating

★★★★★
MDCX's financial health is supported by strong efficiency, including operating-expense and cost-of-revenue discipline (opex 0.0% of revenue). Profitability is weak (1 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
MDCX's growth profile is soft, with the least-weak measure being revenue growth at +0.0% FY2025 versus FY2024. By comparison, while earnings growth (-127.4%, negative) and free-cash-flow growth (-122.3%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 3.5% and approximately 83.9% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 14.77% supports management-shareholder alignment.

Top 5 Institutional Investors

Interchange Capital Partners, LLC 2.21%
Jane Street Group LLC 0.47%
XTX Topco Ltd 0.34%
Sterling Investment Advisors Ltd 0.14%
Commonwealth Equity Services, LLC 0.07%

Unit Economics (Per $1K Revenue)

★★★★★
MDCX generates approximately $0 of gross profit, $-0 of operating income, and $-0 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Weak margins explain the 1-star rating, with weak cash conversion and strong capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
MDCX has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Low VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Clinical Therapeutics & LicensingFuture commercialization milestones, product sales, or licensing revenues derived from pipeline assets like SKNJCT-003 and CD228V.The company currently generates no product revenue and relies on external financing while advancing its clinical pipeline.

Valuation

Trailing PE -
Forward PE -
Enterprise Value 20.12M
Price to Sales(TTM) -
Enterprise Value 20.12M
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding 1.92M
Shares Floating 1.61M
Shares Outstanding 1.92M
Shares Floating 1.61M
Percent Insiders 14.77
Percent Institutions 3.47

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.